Anaplastic large cell lymphoma T- and null-cell types is a rare form of cancer affecting the immune system, where abnormal white blood cells grow out of control. The primary goals of treatment involve controlling the disease, reducing symptoms, and improving quality of life. Treatment choices are made based on the specific characteristics of the cancer cells, the stage of disease, and individual patient factors. Standard chemotherapy remains the backbone of therapy, while ongoing research explores new, targeted treatments designed to work more precisely against the cancer.

Understanding Treatment Goals and Approaches

When someone is diagnosed with anaplastic large cell lymphoma (ALCL) of T- and null-cell types, the treatment team works to achieve several important goals. The main objective is to bring the cancer under control or eliminate it entirely, a state called remission, where cancer cells are no longer detectable in the body. Another critical goal involves reducing symptoms like fever, weight loss, and night sweats—collectively known as B symptoms—which many patients experience at diagnosis. Treatment also aims to prevent the disease from spreading further and to help patients maintain their ability to carry out daily activities and enjoy life.^[1]

The type of treatment a person receives depends on multiple factors. Doctors classify ALCL based on whether the cancer cells produce a specific protein called anaplastic lymphoma kinase, or ALK. Patients with ALK-positive disease, which is more common in children and young adults, typically respond better to standard treatments. Those with ALK-negative disease, usually seen in older adults, may face more challenges because the cancer can return after initial treatment success. The stage of disease—whether it affects only lymph nodes or has spread to organs like the skin, bones, liver, or lungs—also influences treatment decisions.^[1][2]

Medical societies and organizations have established standard treatment protocols based on years of clinical experience and research studies. These guidelines help doctors choose the most effective treatments while minimizing unnecessary side effects. However, medicine continues to evolve, and researchers are constantly investigating new therapies through clinical trials. These studies test promising drugs and treatment approaches that might offer better outcomes or fewer side effects than current options.^[3]

Standard Treatment Approaches

For most patients with systemic ALCL—meaning the disease affects lymph nodes and potentially other organs—chemotherapy forms the foundation of treatment. Chemotherapy refers to powerful medications that kill rapidly dividing cells, including cancer cells. The most widely used chemotherapy regimen for ALCL is called CHOP, which stands for four drugs used together: cyclophosphamide, doxorubicin (also known as hydroxydaunorubicin), vincristine (often called Oncovin), and prednisone. These medications work through different mechanisms to attack cancer cells from multiple angles.^[10]

Cyclophosphamide damages the DNA inside cancer cells, preventing them from multiplying. Doxorubicin interferes with enzymes that cancer cells need to copy their genetic material. Vincristine stops cancer cells from dividing by disrupting the internal structures they use to separate during cell division. Prednisone is a steroid hormone that kills lymphocytes and reduces inflammation. When combined, these four drugs create a powerful treatment that has been used successfully for decades.^[10]

For patients with ALK-positive ALCL, doctors sometimes add a fifth drug called etoposide to the CHOP regimen, creating what’s called CHOEP. This intensified approach has shown particularly good results in younger patients and those with disease that responds well to treatment. The addition of etoposide, which works by damaging DNA and preventing cancer cells from repairing themselves, can improve outcomes for certain patients.^[10]

Chemotherapy is typically given in cycles, which means patients receive treatment for a few days, then have a rest period of several weeks to allow their body to recover before the next cycle begins. Most patients receive six to eight cycles over several months. The exact duration depends on how well the cancer responds and how well the patient tolerates the treatment. During this time, doctors monitor blood counts and perform imaging scans to assess whether the cancer is shrinking.^[1]

When ALCL primarily affects the skin rather than internal organs—a condition called primary cutaneous ALCL—treatment approaches differ significantly. If the disease appears as a single lesion or affects only one area, local treatments may be sufficient. Radiation therapy, which uses high-energy beams to kill cancer cells in a specific area, can successfully treat localized skin disease in about 95 percent of patients. Alternatively, doctors may surgically remove isolated skin lesions through a simple procedure called surgical excision.^[10]

For patients with multiple skin lesions or when skin disease spreads beyond its original location, systemic treatments become necessary. Several medications approved specifically for cutaneous T-cell lymphomas can be used. These include bexarotene (Targretin), which affects how cancer cells grow and die; romidepsin (Istodax) and vorinostat (Zolinza), which work by altering how genes function inside cancer cells; and brentuximab vedotin (Adcetris), a targeted therapy that delivers chemotherapy directly to cancer cells.^[10]

In situations where ALCL does not respond adequately to standard chemotherapy or returns after initial treatment, doctors may recommend more intensive therapy followed by a stem cell transplant. This procedure involves collecting healthy blood-forming cells (stem cells) either from the patient’s own body or from a matched donor. After receiving very high doses of chemotherapy to eliminate remaining cancer cells, the patient receives the collected stem cells through an infusion. These stem cells travel to the bone marrow and begin producing new, healthy blood cells. Stem cell transplantation carries significant risks and requires careful patient selection, but it can offer hope of longer-lasting remission for patients whose disease proves difficult to control with standard approaches.^[3]

Treatment Under Investigation in Clinical Trials

Clinical trials represent an essential avenue for developing better treatments for ALCL. These carefully designed research studies test new drugs, drug combinations, or innovative treatment approaches before they become widely available. Participation in clinical trials gives patients access to cutting-edge therapies while contributing to medical knowledge that will benefit future patients. Trials progress through distinct phases, each with specific purposes.^[3]

Phase I trials focus primarily on safety, determining what dose of a new treatment can be given without causing unacceptable side effects. These studies typically involve small numbers of patients and carefully monitor for any problems. Phase II trials expand to include more patients and aim to determine whether the treatment actually works against the disease. Researchers measure how many patients respond, how long responses last, and continue monitoring safety. Phase III trials compare the new treatment directly against current standard treatments to determine which approach provides better outcomes. These large studies involving hundreds or thousands of patients provide the most reliable evidence about whether a new treatment should replace or supplement existing options.^[3]

One particularly promising area of research involves targeted therapies that work more specifically against ALCL cells while sparing normal cells. Brentuximab vedotin exemplifies this approach. This medication combines an antibody that recognizes CD30—a protein found on the surface of ALCL cells—with a powerful chemotherapy drug. The antibody acts like a guided missile, carrying the chemotherapy directly to cancer cells and releasing it inside them. Because ALCL cells strongly express CD30, brentuximab vedotin can effectively target these cells while causing less damage to normal tissues compared to traditional chemotherapy.^[10]

Clinical trials have studied brentuximab vedotin in various settings for ALCL treatment. Some trials examine its use in patients whose disease has returned after previous treatment (relapsed disease) or never responded adequately to initial therapy (refractory disease). Results from these studies have shown that brentuximab vedotin can produce responses in patients who had limited options, leading to its approval for treating certain forms of ALCL. Other trials are investigating whether adding brentuximab vedotin to standard chemotherapy from the beginning might improve outcomes compared to chemotherapy alone.^[10]

For patients with ALK-positive ALCL, researchers are exploring medications called ALK inhibitors. These drugs specifically block the abnormal ALK protein that drives cancer growth in these patients. The ALK protein results from a genetic rearrangement where part of the ALK gene fuses with another gene, most commonly one called NPM1. This fusion creates an abnormal protein that constantly signals cells to grow and divide. ALK inhibitors interfere with this signal, effectively shutting down one of the cancer’s main growth engines. While ALK inhibitors have been successfully used to treat certain lung cancers with similar genetic changes, research continues to determine their optimal role in treating ALCL.^[1]

Another innovative approach under investigation involves immunotherapy, treatments that harness the body’s own immune system to fight cancer. The immune system normally identifies and destroys abnormal cells, but cancer cells often develop ways to hide from or suppress immune responses. Immunotherapy drugs work by removing these barriers, allowing immune cells to recognize and attack cancer. Some immunotherapy approaches being studied for ALCL include checkpoint inhibitors, which release brakes on immune cells, and CAR T-cell therapy, which involves genetically modifying a patient’s own immune cells to better recognize and kill cancer cells.^[14]

Clinical trials for ALCL are conducted at major cancer centers and research hospitals in many countries, including the United States, Europe, and other regions worldwide. Patients interested in participating need to meet specific eligibility criteria, which vary by study but typically consider factors like disease characteristics, previous treatments received, overall health status, and organ function. Not every patient will qualify for every trial, and some trials may not be available in all geographic areas. Healthcare providers can help patients search for appropriate clinical trials and determine whether participation might be beneficial.^[3]

The decision to join a clinical trial is deeply personal and should involve thorough discussions with the treatment team and loved ones. Potential benefits include accessing new treatments before they’re widely available and receiving care from specialists with extensive expertise in the disease. However, clinical trials also carry uncertainties—new treatments may not work better than standard options, may cause unexpected side effects, or may require more frequent visits and tests than standard treatment. Understanding these factors helps patients make informed decisions aligned with their values and circumstances.^[3]

Most common treatment methods

• Combination chemotherapy regimens
  • CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) represents the standard first-line treatment for systemic ALCL, combining four drugs with different mechanisms of action
  • CHOEP adds etoposide to CHOP, offering more intensive treatment particularly beneficial for ALK-positive disease in younger patients
  • Treatment typically spans six to eight cycles administered over several months, with regular monitoring of response and side effects
• Targeted therapy
  • Brentuximab vedotin (Adcetris) delivers chemotherapy specifically to CD30-positive cancer cells, reducing damage to healthy tissues
  • ALK inhibitors under investigation target the abnormal protein produced by genetic rearrangements in ALK-positive ALCL
  • These approaches aim to improve effectiveness while decreasing side effects compared to traditional chemotherapy
• Radiation therapy
  • Used primarily for localized primary cutaneous ALCL, achieving complete remission in approximately 95% of patients with single lesions
  • High-energy beams target cancer cells in specific body areas while sparing surrounding healthy tissue
  • May be combined with systemic treatments for more extensive disease
• Stem cell transplantation
  • Reserved for patients with relapsed or refractory disease that doesn’t respond adequately to standard treatments
  • Involves high-dose chemotherapy followed by infusion of healthy stem cells to rebuild the blood and immune systems
  • Can use patient’s own cells (autologous transplant) or cells from a matched donor (allogeneic transplant)
• Immunotherapy approaches
  • Under investigation in clinical trials, these treatments activate the patient’s immune system to recognize and destroy cancer cells
  • Includes checkpoint inhibitors that remove immune system brakes and CAR T-cell therapy using genetically modified immune cells
  • Represents a promising area of research for improving outcomes and reducing treatment-related toxicity